<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960997</url>
  </required_header>
  <id_info>
    <org_study_id>35498</org_study_id>
    <nct_id>NCT02960997</nct_id>
  </id_info>
  <brief_title>Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study</brief_title>
  <official_title>A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA
      leading to abnormal dominant keratins in the skin. Patients with EB simplex develop lifelong
      painful thick soles on their feet, and current standard of care is supportive. This pilot
      study will target the dominant mutant keratin proteins in the skin to ameliorate the severity
      of EB simplex. The purpose is to improve the function of EB simplex feet with an application
      of topical sirolimus, 2%. The investigators plan on inhibiting the mTOR pathway to down
      regulate the translation of defective keratin proteins and work through anti proliferative
      pathways.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed 40 week pilot study being conducted is a prospective, double-blind, randomized,
      placebo-controlled crossover study. Participants will be assigned to treat both feet with
      either topical sirolimus, 2% cream daily or placebo (vehicle-control) for 12 weeks, followed
      by a 4 week washout period, then re-treatment to both feet will occur by the cross-over
      intervention.

      These studies will exploit the naturally occurring transcriptional regulation of keratin
      sequences, the known gene aberration causing EB simplex, and assess the potential for mTOR
      pathway inhibition in treatment of the patient's plantar lesions. The objective of this study
      is to assess (1) the safety of topical rapamycin for plantar lesions for the treatment of EB
      simplex, and 2) test if topical rapamycin to improves the clinical severity of lesional skin,
      including pain and itch, in subjects with EB simplex at the end of treatment versus baseline
      and compared to an intrasubject placebo treated control. Wound size measurement, quality of
      life evaluation will be assessed using epidermolysis bullosa (QOLEB), and EB disease activity
      and Scarring Index (EBDASI). With the results of this pilot study, physicians would be able
      to transition from supportive care (the current state of the art for EB simplex) to targeted
      molecular therapeutics, leading to improved mobility and quality of life for patients with EB
      simplex.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 13, 2020</completion_date>
  <primary_completion_date type="Actual">December 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Foot Health Status Questionnaire, Foot Function Domain Score</measure>
    <time_frame>Week 0 and week 12 of the respective treatment period</time_frame>
    <description>Foot function was assessed utilizing the validated Foot Health Status Questionnaire (FHSQ). Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported per intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Foot Health Status Questionnaire, Physical Activity Domain Score</measure>
    <time_frame>Week 0 and week 12 of the respective treatment period</time_frame>
    <description>Physical Activity was assessed utilizing the validated Foot Health Status Questionnaire (FHSQ). Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported per intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration of Sirolimus</measure>
    <time_frame>Week 12</time_frame>
    <description>Trough measurements were taken prior to topical sirolimus administration at the week 12 study visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Steps Per Day Assessed by FitBitÂ® / Pedometer</measure>
    <time_frame>12 weeks</time_frame>
    <description>Average number of steps walked per day from baseline to the end of each treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Dermatological Quality of Life Questionnaire Score</measure>
    <time_frame>Week 0 and week 12 of the respective treatment period</time_frame>
    <description>Quality of Life-Epidermolysis Bullosa (QOLEB) Questionnaire specifically designed for people with EB. The QOLEB can be used to identify everyday life occurrences negatively affected by EB. It assesses change in quality of life over time, an important measure when assessing the success of new treatments for EB. Scores from 0 to 51, with higher scores indicate greater impact of EB on quality of life. Data are reported per intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) Disease Severity Scale Score</measure>
    <time_frame>Week 0 and week 12 of the respective treatment period</time_frame>
    <description>The EBDASI is a validated scoring system that objectively quantifies the severity of EB affecting the entire body. It has been designed to evaluate the response to new therapies for the treatment of EB. Scores range from 0 (absent of EB) to 10 (entire area involved). Data are reported per intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-D Pruritus Scale Score</measure>
    <time_frame>Week 0 and week 12 of the respective treatment period</time_frame>
    <description>The 5-D Pruritus Scale is a 1-page, 5-question tool used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; participants were to rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. After the summation of individual score, the total score ranges from 5 (least affected) to 25 (most affected). Data are reported per intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plantar Defect Size Using 3D Photography</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Plantar defect size measurements using 3D photography (% change in total defect area).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foot Plantar Pressure Measurements</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Foot plantar pressure measurements before and after treatment using the Podotech Elftman Foot Scanner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mTOR Pathway Inhibition</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Molecular biology study of skin biopsies assayed for mTOR pathway inhibition (e.g. determination of phosphoprotein inhibition included ribosomal protein S6, S6 kinase and/or eIF-4E binding protein).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Epidermolysis Bullosa Simplex</condition>
  <condition>Epidermolysis Bullosa Simplex Kobner</condition>
  <condition>Weber-Cockayne Syndrome</condition>
  <arm_group>
    <arm_group_label>Sirolimus, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Sirolimus, 2% topical ointment for 12 weeks followed by placebo to match sirolimus for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then Sirolimus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match sirolimus for 12 weeks followed by Sirolimus, 2% topical ointment for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus, 2%</intervention_name>
    <arm_group_label>Placebo, then Sirolimus</arm_group_label>
    <arm_group_label>Sirolimus, then Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Placebo, then Sirolimus</arm_group_label>
    <arm_group_label>Sirolimus, then Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must:

          -  Be capable of understanding the purpose and risks of the study and sign a written
             Informed Consent Form (ICF); Legally authorized representative of subjects willing and
             able to give consent for children 4-18 yo.

          -  Be male or female with a diagnosis of EBS

          -  Minimum EBDASI feet activity score of 2/10

          -  Age - 4 years or older

          -  Ability to complete 12 study visits within a 40-week period, each for approximately
             30-60 minutes.

          -  Anticipated life expectancy â¥52 weeks.

          -  Males and females of childbearing potential should be using an effective means of
             contraception.

          -  Laboratory values within the range of normal for the participating institution unless
             the PI feels they are not clinically relevant

          -  Be able to comply with all study requirements

        Exclusion Criteria:

          -  Allergy to sirolimus or components of the vehicle ointment

          -  Pregnancy, breast feeding

          -  Prior history of liver disease

          -  Serious known concurrent medical illness or infection, which could potentially present
             a safety risk and/or prevent compliance with the requirements of the treatment
             program.

          -  Known immunodeficiency virus or syndrome including those with:

               -  Acquired Immunodeficiency Syndrome (AIDS)

               -  Human Immunodeficiency Virus (HIV)

               -  Hepatitis B

          -  Prior history of grafting surgeries or other surgeries in the dermatologic treatment
             area

          -  History of significant condition in the dermatologic treatment area such as trauma,
             which could impair evaluation for the treatment of EBS or non-healing chronic wound.

          -  Use of other investigational drugs within 30 days of the screening visit and/or has
             not recovered from any side effects of prior investigational drugs or procedure in the
             affected area (e.g., a biopsy).

          -  Use of acitretin within the last 1 month

          -  Use of Roaccutane within last 3 months

          -  Botox injections to the feet within the last 6 months.

          -  Participant is planning extra physical activities within the next 3 months.

          -  Amputated foot
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce M Teng, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, Marinkovich MP, Martinez AE, McGrath JA, Mellerio JE, Moss C, Murrell DF, Shimizu H, Uitto J, Woodley D, Zambruno G. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014 Jun;70(6):1103-26. doi: 10.1016/j.jaad.2014.01.903. Epub 2014 Mar 29. Review.</citation>
    <PMID>24690439</PMID>
  </reference>
  <reference>
    <citation>Fine JD, Johnson LB, Weiner M, Suchindran C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol. 2004 Mar;29(2):122-7.</citation>
    <PMID>14987264</PMID>
  </reference>
  <reference>
    <citation>Lane EB, McLean WH. Keratins and skin disorders. J Pathol. 2004 Nov;204(4):355-66. Review.</citation>
    <PMID>15495218</PMID>
  </reference>
  <reference>
    <citation>Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ. 2002 Feb;9(2):99-100.</citation>
    <PMID>11840159</PMID>
  </reference>
  <reference>
    <citation>Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002 Feb;8(2):128-35.</citation>
    <PMID>11821896</PMID>
  </reference>
  <reference>
    <citation>Fogel AL, Hill S, Teng JM. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology. J Am Acad Dermatol. 2015 May;72(5):879-89. doi: 10.1016/j.jaad.2015.01.014. Epub 2015 Mar 11. Review.</citation>
    <PMID>25769191</PMID>
  </reference>
  <reference>
    <citation>Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7037-44. Review.</citation>
    <PMID>11416184</PMID>
  </reference>
  <reference>
    <citation>Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci. 2009 Nov;56(2):82-8. doi: 10.1016/j.jdermsci.2009.07.008. Epub 2009 Aug 21.</citation>
    <PMID>19699613</PMID>
  </reference>
  <reference>
    <citation>Riskowski JL, Hagedorn TJ, Hannan MT. Measures of foot function, foot health, and foot pain: American Academy of Orthopedic Surgeons Lower Limb Outcomes Assessment: Foot and Ankle Module (AAOS-FAM), Bristol Foot Score (BFS), Revised Foot Function Index (FFI-R), Foot Health Status Questionnaire (FHSQ), Manchester Foot Pain and Disability Index (MFPDI), Podiatric Health Questionnaire (PHQ), and Rowan Foot Pain Assessment (ROFPAQ). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S229-39. doi: 10.1002/acr.20554. Review.</citation>
    <PMID>22588747</PMID>
  </reference>
  <reference>
    <citation>Loh CC, Kim J, Su JC, Daniel BS, Venugopal SS, Rhodes LM, Intong LR, Law MG, Murrell DF. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). J Am Acad Dermatol. 2014 Jan;70(1):89-97.e1-13. doi: 10.1016/j.jaad.2013.09.041.</citation>
    <PMID>24355263</PMID>
  </reference>
  <reference>
    <citation>Venugopal SS, Yan W, Frew JW, Cohn HI, Rhodes LM, Tran K, Melbourne W, Nelson JA, Sturm M, Fogarty J, Marinkovich MP, Igawa S, Ishida-Yamamoto A, Murrell DF. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2013 Dec;69(6):898-908.e7. doi: 10.1016/j.jaad.2013.08.014. Epub 2013 Sep 24.</citation>
    <PMID>24075228</PMID>
  </reference>
  <reference>
    <citation>Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol. 2009 Dec;161(6):1323-30. doi: 10.1111/j.1365-2133.2009.09347.x. Epub 2009 Jun 11. Erratum in: Br J Dermatol. 2010 Mar;162(3):701.</citation>
    <PMID>19681875</PMID>
  </reference>
  <reference>
    <citation>Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010 Mar;162(3):587-93. doi: 10.1111/j.1365-2133.2009.09586.x. Epub 2009 Dec 1.</citation>
    <PMID>19995367</PMID>
  </reference>
  <reference>
    <citation>Storm FA, Heller BW, MazzÃ  C. Step detection and activity recognition accuracy of seven physical activity monitors. PLoS One. 2015 Mar 19;10(3):e0118723. doi: 10.1371/journal.pone.0118723. eCollection 2015.</citation>
    <PMID>25789630</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <results_first_submitted>December 14, 2019</results_first_submitted>
  <results_first_submitted_qc>January 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2020</results_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Joyce Teng</investigator_full_name>
    <investigator_title>Director of Pediatric Dermatology</investigator_title>
  </responsible_party>
  <keyword>epidermolysis bullosa simplex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cockayne Syndrome</mesh_term>
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02960997/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus, Then Placebo</title>
          <description>Participants will receive Sirolimus, 2% topical ointment for 12 weeks followed by placebo to match sirolimus for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Sirolimus</title>
          <description>Participants will receive placebo to match sirolimus for 12 weeks followed by Sirolimus, 2% topical ointment for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention, 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period, 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Treatment, 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Period, 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus, Then Placebo</title>
          <description>Participants will receive Sirolimus, 2% topical ointment for 12 weeks followed by placebo to match sirolimus for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Then Sirolimus</title>
          <description>Participants will receive placebo to match sirolimus for 12 weeks followed by Sirolimus, 2% topical ointment for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Foot Health Status Questionnaire, Foot Function</title>
          <description>Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported according to randomization group.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.6" spread="11.16"/>
                    <measurement group_id="B2" value="51.6" spread="20.90"/>
                    <measurement group_id="B3" value="51.6" spread="16.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Foot Health Status Questionnaire, Physical Activity</title>
          <description>Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported according to randomization group.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="25.00"/>
                    <measurement group_id="B2" value="54.2" spread="22.35"/>
                    <measurement group_id="B3" value="59.0" spread="24.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child Dermatological Quality of Life Questionnaire</title>
          <description>Quality of Life-Epidermolysis Bullosa (QOLEB) scores range from 0 to 51; higher scores indicate greater impact of EB on quality of life. Data are reported according to randomization group.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.0" spread="10.17"/>
                    <measurement group_id="B2" value="17.3" spread="4.60"/>
                    <measurement group_id="B3" value="17.6" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) Disease Severity Scale</title>
          <description>Scores range from 0 (absent of EB) to 10 (entire area involved). Data are reported according to randomization group.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="0.43"/>
                    <measurement group_id="B2" value="3.5" spread="0.87"/>
                    <measurement group_id="B3" value="3.1" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>5-D Pruritus Score</title>
          <description>Total score ranges from 5 (least affected) to 25 (most affected). Data are reported according to randomization group.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.0" spread="1.87"/>
                    <measurement group_id="B2" value="11.0" spread="2.35"/>
                    <measurement group_id="B3" value="13.0" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Foot Health Status Questionnaire, Foot Function Domain Score</title>
        <description>Foot function was assessed utilizing the validated Foot Health Status Questionnaire (FHSQ). Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported per intervention.</description>
        <time_frame>Week 0 and week 12 of the respective treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Sirolimus, 2% topical ointment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match sirolimus for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Foot Health Status Questionnaire, Foot Function Domain Score</title>
          <description>Foot function was assessed utilizing the validated Foot Health Status Questionnaire (FHSQ). Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported per intervention.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="26.48"/>
                    <measurement group_id="O2" value="49.3" spread="20.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2" spread="23.37"/>
                    <measurement group_id="O2" value="56.3" spread="24.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Foot Health Status Questionnaire, Physical Activity Domain Score</title>
        <description>Physical Activity was assessed utilizing the validated Foot Health Status Questionnaire (FHSQ). Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported per intervention.</description>
        <time_frame>Week 0 and week 12 of the respective treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Sirolimus, 2% topical ointment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match sirolimus for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Foot Health Status Questionnaire, Physical Activity Domain Score</title>
          <description>Physical Activity was assessed utilizing the validated Foot Health Status Questionnaire (FHSQ). Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported per intervention.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" spread="24.37"/>
                    <measurement group_id="O2" value="54.2" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" spread="20.37"/>
                    <measurement group_id="O2" value="61.8" spread="24.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough Concentration of Sirolimus</title>
        <description>Trough measurements were taken prior to topical sirolimus administration at the week 12 study visit.</description>
        <time_frame>Week 12</time_frame>
        <population>Trough concentration of sirolimus was collected during Sirolimus treatment only, so the Placebo group is not presented in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Sirolimus, 2% topical ointment for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentration of Sirolimus</title>
          <description>Trough measurements were taken prior to topical sirolimus administration at the week 12 study visit.</description>
          <population>Trough concentration of sirolimus was collected during Sirolimus treatment only, so the Placebo group is not presented in this outcome measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">All measurements were below the lower limit of quantitation (&lt;2 ng/mL).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Steps Per Day Assessed by FitBitÂ® / Pedometer</title>
        <description>Average number of steps walked per day from baseline to the end of each treatment.</description>
        <time_frame>12 weeks</time_frame>
        <population>One participant had no Fitbit data during placebo treatment and is excluded from the analysis. Three participants lost their Fitbit devices for week 12 reporting during sirolimus treatment; their data through week 8 are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Sirolimus, 2% topical ointment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match sirolimus for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Average Steps Per Day Assessed by FitBitÂ® / Pedometer</title>
          <description>Average number of steps walked per day from baseline to the end of each treatment.</description>
          <population>One participant had no Fitbit data during placebo treatment and is excluded from the analysis. Three participants lost their Fitbit devices for week 12 reporting during sirolimus treatment; their data through week 8 are included in the analysis.</population>
          <units>steps</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6624" spread="1847"/>
                    <measurement group_id="O2" value="7130" spread="3025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Child Dermatological Quality of Life Questionnaire Score</title>
        <description>Quality of Life-Epidermolysis Bullosa (QOLEB) Questionnaire specifically designed for people with EB. The QOLEB can be used to identify everyday life occurrences negatively affected by EB. It assesses change in quality of life over time, an important measure when assessing the success of new treatments for EB. Scores from 0 to 51, with higher scores indicate greater impact of EB on quality of life. Data are reported per intervention.</description>
        <time_frame>Week 0 and week 12 of the respective treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Sirolimus, 2% topical ointment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match sirolimus for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Child Dermatological Quality of Life Questionnaire Score</title>
          <description>Quality of Life-Epidermolysis Bullosa (QOLEB) Questionnaire specifically designed for people with EB. The QOLEB can be used to identify everyday life occurrences negatively affected by EB. It assesses change in quality of life over time, an important measure when assessing the success of new treatments for EB. Scores from 0 to 51, with higher scores indicate greater impact of EB on quality of life. Data are reported per intervention.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="9.37"/>
                    <measurement group_id="O2" value="6.6" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="10.14"/>
                    <measurement group_id="O2" value="13.3" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) Disease Severity Scale Score</title>
        <description>The EBDASI is a validated scoring system that objectively quantifies the severity of EB affecting the entire body. It has been designed to evaluate the response to new therapies for the treatment of EB. Scores range from 0 (absent of EB) to 10 (entire area involved). Data are reported per intervention.</description>
        <time_frame>Week 0 and week 12 of the respective treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Sirolimus, 2% topical ointment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match sirolimus for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) Disease Severity Scale Score</title>
          <description>The EBDASI is a validated scoring system that objectively quantifies the severity of EB affecting the entire body. It has been designed to evaluate the response to new therapies for the treatment of EB. Scores range from 0 (absent of EB) to 10 (entire area involved). Data are reported per intervention.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.32"/>
                    <measurement group_id="O2" value="3.5" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.54"/>
                    <measurement group_id="O2" value="2.5" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-D Pruritus Scale Score</title>
        <description>The 5-D Pruritus Scale is a 1-page, 5-question tool used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; participants were to rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. After the summation of individual score, the total score ranges from 5 (least affected) to 25 (most affected). Data are reported per intervention.</description>
        <time_frame>Week 0 and week 12 of the respective treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Sirolimus, 2% topical ointment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match sirolimus for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>5-D Pruritus Scale Score</title>
          <description>The 5-D Pruritus Scale is a 1-page, 5-question tool used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; participants were to rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. After the summation of individual score, the total score ranges from 5 (least affected) to 25 (most affected). Data are reported per intervention.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="3.03"/>
                    <measurement group_id="O2" value="11.5" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="3.46"/>
                    <measurement group_id="O2" value="11.8" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plantar Defect Size Using 3D Photography</title>
        <description>Plantar defect size measurements using 3D photography (% change in total defect area).</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>Data were not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Sirolimus, 2% topical ointment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match sirolimus for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plantar Defect Size Using 3D Photography</title>
          <description>Plantar defect size measurements using 3D photography (% change in total defect area).</description>
          <population>Data were not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Foot Plantar Pressure Measurements</title>
        <description>Foot plantar pressure measurements before and after treatment using the Podotech Elftman Foot Scanner.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>Data were not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Sirolimus, 2% topical ointment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match sirolimus for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Foot Plantar Pressure Measurements</title>
          <description>Foot plantar pressure measurements before and after treatment using the Podotech Elftman Foot Scanner.</description>
          <population>Data were not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in mTOR Pathway Inhibition</title>
        <description>Molecular biology study of skin biopsies assayed for mTOR pathway inhibition (e.g. determination of phosphoprotein inhibition included ribosomal protein S6, S6 kinase and/or eIF-4E binding protein).</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>Data were not collected for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Sirolimus, 2% topical ointment for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match sirolimus for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in mTOR Pathway Inhibition</title>
          <description>Molecular biology study of skin biopsies assayed for mTOR pathway inhibition (e.g. determination of phosphoprotein inhibition included ribosomal protein S6, S6 kinase and/or eIF-4E binding protein).</description>
          <population>Data were not collected for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>32 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus</title>
          <description>Sirolimus, 2% topical ointment for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to match sirolimus for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose stool</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upset stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Feet pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased foot pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction to antiobiotic (sulfamethoxole)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Seasonal allergies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <description>1 event occurred during the follow-up period</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>High fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Leg infected lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Right footstaph infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Food poisioning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Right and left leg abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Right thigh abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Painful urination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation on feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joyce Teng, MD, PhD</name_or_title>
      <organization>Stanford University</organization>
      <phone>(650) 724-9627</phone>
      <email>jteng3@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

